Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Clinical Toxicology (Philadelphia, Pa.)
|
April 20, 2017
The management of ventricular dysrhythmia in aconite poisoning
James M Coulson, Thomas M Caparrotta, John P Thompson
European Journal of Clinical Pharmacology
|
October 26, 2017
Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature
Thomas M Caparrotta, Daniel J Antoine, James W Dear
British Journal of Clinical Pharmacology
|
June 18, 2019
Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making
Thomas M Caparrotta, James W Dear, Helen M Colhoun, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 26, 2021
Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M Caparrotta, Jack B Templeton, Thomas A Clay, et al.
Brain Communications
|
November 19, 2025
Risk of cardiovascular and autoimmune disease in people with multiple sclerosis on long-term interferon-β therapy
Bastien Rioux, Feng Zhu, Huah Shin Ng, et al.
Emergency Medicine Journal : EMJ
|
August 24, 2025
Scottish and Newcastle Antiemetic Protocol (SNAP) 12-hour acetylcysteine regimen for paracetamol overdose reduces anaphylactoid reactions without compromising hepatic protection in all age groups: a secondary analysis
Christopher Humphries, Janice Pettie, Bridget Agboola, et al.
Diabetes Care
|
July 26, 2022
Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland
Paul M McKeigue, Stuart McGurnaghan, Luke Blackbourn, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
March 5, 2021
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M Caparrotta, Andrew M Greenhalgh, Karen Osinski, et al.
Diabetes Care
|
June 18, 2024
Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland
Stuart J McGurnaghan, Paul M McKeigue, Luke A K Blackbourn, et al.
Diabetes Care
|
June 26, 2020
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
Thomas M Caparrotta, Luke A K Blackbourn, Stuart J McGurnaghan, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Clinical Toxicology (Philadelphia, Pa.)
|
April 20, 2017
The management of ventricular dysrhythmia in aconite poisoning
James M Coulson, Thomas M Caparrotta, John P Thompson
European Journal of Clinical Pharmacology
|
October 26, 2017
Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature
Thomas M Caparrotta, Daniel J Antoine, James W Dear
British Journal of Clinical Pharmacology
|
June 18, 2019
Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making
Thomas M Caparrotta, James W Dear, Helen M Colhoun, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 26, 2021
Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M Caparrotta, Jack B Templeton, Thomas A Clay, et al.
Brain Communications
|
November 19, 2025
Risk of cardiovascular and autoimmune disease in people with multiple sclerosis on long-term interferon-β therapy
Bastien Rioux, Feng Zhu, Huah Shin Ng, et al.
Emergency Medicine Journal : EMJ
|
August 24, 2025
Scottish and Newcastle Antiemetic Protocol (SNAP) 12-hour acetylcysteine regimen for paracetamol overdose reduces anaphylactoid reactions without compromising hepatic protection in all age groups: a secondary analysis
Christopher Humphries, Janice Pettie, Bridget Agboola, et al.
Diabetes Care
|
July 26, 2022
Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland
Paul M McKeigue, Stuart McGurnaghan, Luke Blackbourn, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
March 5, 2021
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M Caparrotta, Andrew M Greenhalgh, Karen Osinski, et al.
Diabetes Care
|
June 18, 2024
Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland
Stuart J McGurnaghan, Paul M McKeigue, Luke A K Blackbourn, et al.
Diabetes Care
|
June 26, 2020
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
Thomas M Caparrotta, Luke A K Blackbourn, Stuart J McGurnaghan, et al.
Page
of 3